Diagnosis and Treatment > Medication > Mecasermin
You are looking at 1 - 1 of 1 items
Fundación de Investigación HM Hospitales, Madrid, Spain
Search for other papers by I Castilla-Cortazar in
Google Scholar
PubMed
Search for other papers by J R De Ita in
Google Scholar
PubMed
Search for other papers by G A Aguirre in
Google Scholar
PubMed
Search for other papers by M García–Magariño in
Google Scholar
PubMed
Search for other papers by I Martín-Estal in
Google Scholar
PubMed
Search for other papers by V J Lara-Diaz in
Google Scholar
PubMed
Search for other papers by M I Elizondo in
Google Scholar
PubMed
Summary
Herein, we present a 14-year-old patient with short stature (134 cm) referred from Paediatrics to our department for complementary evaluation since growth hormone (GH) treatment failed to show any improvement. He was born premature and small for gestational age. Genital examination classified the patient as Tanner I–II with small penis and testicular size for his age. Biochemical analyses revealed normal GH levels with low serum insulin-like growth factor-1 (IGF-1). Molecular diagnosis confirmed several mutations in IGF1R and IGFALS, and so he was diagnosed with Laron Syndrome or GH insensibility and treated with IGF-1 substitutive therapy.
Learning points:
-
Evaluation of the GH/IGF-1 axis when short stature does not respond to conservative treatment must be included in the ordinary practice.
-
Laron Syndrome real incidence should be calculated once undiagnosed cases arise, as treatment, due to lack of market, is unaffordable.
-
Even when adulthood is reached, and no longitudinal growth can be achieved, still IGF-1 treatment in Laron Syndrome patients should be pursued as metabolic and protective derangements could arise.
